CDEK by Data4ThePeople
Sign in Sign up
← All drugs Report issue

suramin

Small moleculeexperimental

Suramin is a medication used to treat African sleeping sickness and river blindness. It is the treatment of choice for sleeping sickness without central nervous system involvement. It is given by injection into a vein. — Wikipedia

Clinical trial activity

21 trials · 26 clinical orgs · 0 marketing orgs

Phase 1
8
Phase 2
16
Phase 3
2
Phase 4
0

Earliest trial started Oct 1, 1990 (NCT00001266)

Timeline

1990s

  1. Jan 1, 1990

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 1994

    Earliest Phase 1 Sponsor(trial)

  3. Jan 1, 1996

    Earliest Phase 3 Sponsor(trial)

Indications

Studied for

Mechanism of action

  • Acidic fibroblast growth factorINHIBITOR

    FGF1 inhibitor

    Potent inhibitor of fibroblast growth factor-induced angiogenesis through binding to FGF1. Also blocks binding several other growth factors to their receptors. Competitive inhibitor of GAGs and heparin, has been shown to have antiviral activity (HIV, HSV-1, HBV, HCV, dengue virus, EV71, Rift Valley Fever Virus, CHIKV and EBOV). Non-specific potent inhibitor of reverse transcriptases of several retroviruses (HTLV-III/LAV) and also inhibits DNA polymerases (DNA primase, DNA polymerase alpha).

    Binds to fibroblast growth factor 1 in a hydrophobic manner at L14, C16, L133, and L135 residues

Chemistry & pharmacology

Loading structure…

SMILES

Cc1ccc(C(=O)Nc2ccc(S(=O)(=O)O)c3cc(S(=O)(=O)O)cc(S(=O)(=O)O)c23)cc1NC(=O)c1cccc(NC(=O)Nc2cccc(C(=O)Nc3cc(C(=O)Nc4ccc(S(=O)(=O)O)c5cc(S(=O)(=O)O)cc(S(=O)(=O)O)c45)ccc3C)c2)c1
Mol. weight
1297.3 g/mol
Chirality
Achiral Molecule
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • 8,8'-[carbonylbis[imino-3,1-phenylenecarbonylimino(4-methyl-3,1-phenylene)carbonylimino]]bis-1,3,5-naphthalenetrisulfonic acid
  • 8,8'-[carbonylbis[imino-3,1-phenylenecarbonylimino(4-methyl-3,1-phenylene)carbonylimino]]bis-1,3,5-naphthalenetrisulfonic acid
  • belganyl
  • belganyl
  • ci-1003
  • ci-1003
  • metaret
  • naganol
  • naganol
  • naganol
  • naphuride
  • naphuride
  • naphuride
  • suramin
  • suramin
  • suramin
  • suramin
  • suramin
  • suramin
  • suramin
  • suramin
  • suramin
  • suramine
  • suramine
  • suramine
  • suramin hexasodium
  • suramin hexasodium
  • suramin hexasodium
  • suramin sodium
  • suramin sodium
  • suramin sodium
  • suramin sodium

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06866275Phase 2Apr 30, 2025University of California, Irvine
NCT04496596Phase 2Sep 30, 2020Rediscovery Life Sciences
NCT06058962Phase 2Jun 1, 2019Paxmedica
NCT03804749Phase 1Dec 19, 2018Guangdong Kangda Pharmaceutical Co., Ltd, Zhejiang University
NCT02508259Phase 1/Phase 2 (Phase 2)May 1, 2015University of California, San Diego
NCT01671332Phase 2Jun 1, 2012Medical College of Wisconsin, Ohio State University, Optimum Therapeutics, LLC, University of Wisconsin
NCT01038752Phase 2Aug 1, 2010Optimum Therapeutics, LLC
NCT00083109Phase 1/Phase 2 (Phase 2)Mar 1, 2004National Cancer Institute (NCI), University of Rochester
NCT00066768Phase 1Jul 1, 2003National Cancer Institute (NCI), Ohio State University
NCT00054028Phase 1/Phase 2 (Phase 2)Dec 1, 2002National Cancer Institute (NCI), Ohio State University
NCT00006476Phase 1Oct 1, 2000Cancer Research UK, University of Oxford
NCT00006929Phase 2Sep 1, 2000National Cancer Institute (NCI), Ohio State University
NCT00004073Phase 2Dec 1, 1999Johns Hopkins University, National Cancer Institute (NCI)
NCT00003038Phase 1Oct 1, 1997Mayo Clinic, National Cancer Institute (NCI)
NCT00002921Phase 2Mar 1, 1997National Cancer Institute (NCI), Southwest Oncology Group, University of Cincinnati
NCT00002881Phase 3Oct 1, 1996Cancer and Leukemia Group B (CALGB), Eastern Cooperative Oncology Group, Louisiana State University, National Cancer Institute (NCI), Southwest Oncology Group, United States Army, University of Wisconsin
NCT00002723Phase 3Jan 1, 1996Eastern Cooperative Oncology Group, Herbert Irving Comprehensive Cancer Center, National Cancer Institute (NCI), Southwest Oncology Group, University of California, San Francisco, University of Wisconsin
NCT00002639Phase 2Jul 1, 1995Emory University, National Cancer Institute (NCI)
NCT00002652Phase 2May 1, 1995Hoosier Cancer Research Network, National Cancer Institute (NCI)
NCT00001381Phase 1Mar 1, 1994National Cancer Institute (NCI)
Showing 20 of 21 trials
Page 1 / 2

Organizations

Research & Development (26)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
National Cancer Institute (NCI)Government13731990
Ohio State UniversityAcademic/Hospital4022000
Southwest Oncology GroupAcademic/Hospital3121996
University of WisconsinAcademic/Hospital3121996
Eastern Cooperative Oncology GroupAcademic/Hospital2111996
Optimum Therapeutics, LLCFor profit2112010
Cancer and Leukemia Group B (CALGB)Academic/Hospital1011996
Cancer Research UKAcademic/Hospital1112000
Emory UniversityAcademic/Hospital1111995
Guangdong Kangda Pharmaceutical Co., LtdFor profit1012018
Herbert Irving Comprehensive Cancer CenterAcademic/Hospital1011996
Hoosier Cancer Research NetworkAcademic/Hospital1111995
Johns Hopkins UniversityAcademic/Hospital1111999
Louisiana State UniversityAcademic/Hospital1011996
Mayo ClinicAcademic/Hospital1111997
Medical College of WisconsinAcademic/Hospital1012012
PaxmedicaFor profit1112019
Rediscovery Life SciencesFor profit1112020
United States ArmyGovernment1011996
University of California, IrvineAcademic/Hospital1112025
26 organizations
Page 1 / 2